# CRON — Cronos Group · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** CRON  
**Sources:** 19  
**Published:** 2026-10-03  
**Canonical:** https://app.k3vl4r.com/research/deep-research-cron-cronos-group-catalysts-narrative-risks-5885

---

## Snapshot (as of Oct 2, 2026)

As of the Oct 2, 2026 close, CRON traded around $3.22–$3.23 with a market capitalization near $1.19 billion, sitting close to the top of its 52-week range ($2.28–$3.61) [[15]](https://finance.yahoo.com/quote/CRON/)[[17]](https://www.marketbeat.com/stocks/NASDAQ/CRON/). Trailing twelve-month (TTM) figures show a P/E near 16, TTM EPS of $0.19, TTM revenue of ~$179 million, TTM net income of ~$70 million, cash of ~$797 million, and a Total Debt/Equity ratio of just 0.12% [[15]](https://finance.yahoo.com/quote/CRON/). The stock is dual-listed on NASDAQ (CRON) and the TSX (CRON), and is described by one source as Health Care / Pharmaceuticals & Cannabis, even though a separate internal universe file classifies it under consumer_staples [[10]](https://www.ad-hoc-news.de/boerse/news/ueberblick/cronos-group-stock-analyst-views-and-long-term-cannabis-strategy/69592773)[[17]](https://www.marketbeat.com/stocks/NASDAQ/CRON/). The stock is up roughly 40% over the past year [[5]](https://finance.yahoo.com/markets/stocks/articles/cronos-group-inc-cron-stock-121537565.html).

## Recent catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-cron-cronos-group-catalysts-narrative-risks-5885 (free to sign up)._
